Literature DB >> 12711684

Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles.

Ekambar R Kandimalla1, Lakshmi Bhagat, Daqing Wang, Dong Yu, Fu-Gang Zhu, Jimmy Tang, Hui Wang, Ping Huang, Ruiwen Zhang, Sudhir Agrawal.   

Abstract

Unmethylated CpG dinucleotides present within certain specific sequence contexts in bacterial and synthetic DNA stimulate innate immune responses and induce cytokine secretion. Recently, we showed that CpG DNAs containing two 5'-ends, immunomers, are more potent in both regards. In this study, we show that an immunomer containing a synthetic CpR motif (R = 2'-deoxy-7-deazaguanosine) is a potent immunostimulatory agent. However, the profile of cytokine induction is different from that with immunomers containing a natural CpG motif. In general, a CpR immunomer induced higher interleukin (IL)-12 and lower IL-6 secretion. Compared with conventional CpG DNAs, both types of immunomers showed a rapid and enhanced activation of the transcription factor NF-kappaB in J774 cells. NF-kappaB activation by CpG DNA corresponded to degradation of IkappaBalpha in J774 cells. All three immunostimulatory oligonucleotides activated the p38 mitogen-activated protein kinase pathway as expected. Immunomers containing CpG and CpR motifs showed potent reversal of the antigen-induced Th2 immune response towards a Th1 type in antigen-sensitized mouse spleen cell cultures. Immunomers containing a CpR motif showed significant antitumor activity in nude mice bearing MCF-7 human breast cancer and U87MG glioblastoma xenografts. These studies suggest the ability for a divergent synthetic nucleotide motif recognition pattern of the receptor involved in the immunostimulatory pathway and the possibility of using synthetic nucleotides to elicit different cytokine response patterns.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12711684      PMCID: PMC154229          DOI: 10.1093/nar/gkg343

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  49 in total

1.  Accessible 5'-end of CpG-containing phosphorothioate oligodeoxynucleotides is essential for immunostimulatory activity.

Authors:  D Yu; Q Zhao; E R Kandimalla; S Agrawal
Journal:  Bioorg Med Chem Lett       Date:  2000-12-04       Impact factor: 2.823

2.  A Toll-like receptor recognizes bacterial DNA.

Authors:  H Hemmi; O Takeuchi; T Kawai; T Kaisho; S Sato; H Sanjo; M Matsumoto; K Hoshino; H Wagner; K Takeda; S Akira
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

Review 3.  Introduction to immunostimulatory DNA sequences.

Authors:  J Van Uden; E Raz
Journal:  Springer Semin Immunopathol       Date:  2000

Review 4.  Activation of the innate immune system by CpG oligodeoxynucleotides: immunoprotective activity and safety.

Authors:  D M Klinman; S Kamstrup; D Verthelyi; I Gursel; K J Ishii; F Takeshita; M Gursel
Journal:  Springer Semin Immunopathol       Date:  2000

Review 5.  The role of immunostimulatory CpG-DNA in septic shock.

Authors:  H Wagner; G B Lipford; H Häcker
Journal:  Springer Semin Immunopathol       Date:  2000

Review 6.  Towards the rational design of Th1 adjuvants.

Authors:  P Moingeon; J Haensler; A Lindberg
Journal:  Vaccine       Date:  2001-08-14       Impact factor: 3.641

Review 7.  Towards optimal design of second-generation immunomodulatory oligonucleotides.

Authors:  Ekambar R Kandimalla; Dong Yu; Sudhir Agrawal
Journal:  Curr Opin Mol Ther       Date:  2002-04

8.  Site of chemical modifications in CpG containing phosphorothioate oligodeoxynucleotide modulates its immunostimulatory activity.

Authors:  Q Zhao; D Yu; S Agrawal
Journal:  Bioorg Med Chem Lett       Date:  1999-12-20       Impact factor: 2.823

9.  Effect of chemical modifications of cytosine and guanine in a CpG-motif of oligonucleotides: structure-immunostimulatory activity relationships.

Authors:  E R Kandimalla; D Yu; Q Zhao; S Agrawal
Journal:  Bioorg Med Chem       Date:  2001-03       Impact factor: 3.641

10.  CpG oligodeoxynucleotides can reverse Th2-associated allergic airway responses and alter the B7.1/B7.2 expression in a murine model of asthma.

Authors:  D Serebrisky; A A Teper; C K Huang; S Y Lee; T F Zhang; B H Schofield; M Kattan; H A Sampson; X M Li
Journal:  J Immunol       Date:  2000-11-15       Impact factor: 5.422

View more
  12 in total

1.  Immunomodulatory oligonucleotides containing a cytosine-phosphate-2'-deoxy-7-deazaguanosine motif as potent toll-like receptor 9 agonists.

Authors:  Ekambar R Kandimalla; Lakshmi Bhagat; Yukui Li; Dong Yu; Daqing Wang; Yan-Ping Cong; Sam S Song; Jimmy X Tang; Tim Sullivan; Sudhir Agrawal
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-28       Impact factor: 11.205

2.  Immune-Stimulatory Dinucleotide at the 5'-End of Oligodeoxynucleotides Is Critical for TLR9-Mediated Immune Responses.

Authors:  Mallikarjuna R Putta; Lakshmi Bhagat; Daqing Wang; Fu-Gang Zhu; Ekambar R Kandimalla; Sudhir Agrawal
Journal:  ACS Med Chem Lett       Date:  2013-01-29       Impact factor: 4.345

3.  Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF.

Authors:  Angelo Corti; Monica Giovannini; Carmen Belli; Eugenio Villa
Journal:  J Oncol       Date:  2010-06-03       Impact factor: 4.375

4.  Impact of secondary structure of toll-like receptor 9 agonists on interferon alpha induction.

Authors:  Dong Yu; Mallikarjuna R Putta; Lakshmi Bhagat; Meiru Dai; Daqing Wang; Anthony F Trombino; Tim Sullivan; Ekambar R Kandimalla; Sudhir Agrawal
Journal:  Antimicrob Agents Chemother       Date:  2008-10-13       Impact factor: 5.191

5.  A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif.

Authors:  Ekambar R Kandimalla; Lakshmi Bhagat; Fu-Gang Zhu; Dong Yu; Yan-Ping Cong; Daqing Wang; Jimmy X Tang; Jin-Yan Tang; Cathrine F Knetter; Egil Lien; Sudhir Agrawal
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-10       Impact factor: 11.205

6.  TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts.

Authors:  Vincenzo Damiano; Rosa Caputo; Sonia Garofalo; Roberto Bianco; Roberta Rosa; Gerardina Merola; Teresa Gelardi; Luigi Racioppi; Gabriella Fontanini; Sabino De Placido; Ekambar R Kandimalla; Sudhir Agrawal; Fortunato Ciardiello; Giampaolo Tortora
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-16       Impact factor: 11.205

7.  TLR9 agonist protects mice from radiation-induced gastrointestinal syndrome.

Authors:  Subhrajit Saha; Payel Bhanja; Laibin Liu; Alan A Alfieri; Dong Yu; Ekambar R Kandimalla; Sudhir Agrawal; Chandan Guha
Journal:  PLoS One       Date:  2012-01-04       Impact factor: 3.240

8.  An in situ autologous tumor vaccination with combined radiation therapy and TLR9 agonist therapy.

Authors:  Huagang Zhang; Laibin Liu; Dong Yu; Ekambar R Kandimalla; Hui Bin Sun; Sudhir Agrawal; Chandan Guha
Journal:  PLoS One       Date:  2012-05-30       Impact factor: 3.240

9.  Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9.

Authors:  Ekambar R Kandimalla; Lakshmi Bhagat; Daqing Wang; Dong Yu; Tim Sullivan; Nicola La Monica; Sudhir Agrawal
Journal:  Nucleic Acids Res       Date:  2013-02-08       Impact factor: 16.971

10.  Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis.

Authors:  V Damiano; R Rosa; L Formisano; L Nappi; T Gelardi; R Marciano; I Cozzolino; G Troncone; S Agrawal; B M Veneziani; S De Placido; R Bianco; G Tortora
Journal:  Br J Cancer       Date:  2013-04-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.